VC Fund Dossiers

Advent Life Sciences is the real deal - a proper company builder that actually gets drugs approved, not just another PowerPoint VC. Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A. Their crown jewel was KaNDy Therapeutics, which they spun out and sold to Bayer for $875 million - that's the kind of outcome that gets LPs' attention. The partners have genuine biotech operational experience, not just finance backgrounds, and they're hands-on without being micromanaging. They're particularly strong at company formation and early-stage value creation. The team is lean but experienced, with good transatlantic reach through their Boston presence. However, their portfolio is quite concentrated in traditional biopharma plays - if you're doing digital health or medical devices, this might not be your first call.

APEX Ventures is the rare European deep tech fund that actually understands what they're investing in - probably because their partners have real operational experience rather than just finance backgrounds. Andreas Riegler built and sold companies before becoming a VC, Wolfgang Neubert has deep technical expertise in photonics and quantum, and Gordon Euller is a practicing radiologist who worked at McKinsey. This translates into genuine value-add for founders wrestling with complex IP strategies and brutal commercialization timelines. The €80M Amadeus APEX Technology Fund partnership gives them serious firepower, and their portfolio companies consistently praise their hands-on support and network introductions. However, they're primarily focused on DACH region deals, so if you're not in Germany/Austria/Switzerland, you might be swimming upstream. Also, while they talk a good game about being 'founder-friendly,' deep tech investors by nature tend to want more control given the long development cycles and capital intensity.

This is classic old-school UK venture capital - the kind that's been around since 1999 and has the battle scars to prove it. They've delivered solid returns with 14 profitable exits since 2015 averaging 4.7x, including some standout wins like R2C Online at 12.6x and Accutronics at 9.1x. What's refreshing is they actually take board seats and get their hands dirty - each partner has direct portfolio responsibility and they're not afraid to help with hiring, customer introductions, and financial strategy. With £130m under management, they're mid-sized but experienced. The downside? They're a small team (2-10 employees) which means limited bandwidth, and their heavy life sciences focus means if you're not in healthcare/biotech, you're probably not their cup of tea. They seem genuinely committed to long-term value creation rather than quick flips, which is either exactly what you want or frustratingly slow depending on your timeline.